难治性晚期KIT外显子9突变胃肠间质瘤患者的治疗探索:靶向联合治疗加肿瘤减灭术
Treatment exploration of patients with refractory advanced KIT exon 9 mutant gastrointestinal stromal tumors:combination targeted therapy and cytoreductive surgery
颜淼 1夏延哲 2张信华1
作者信息
- 1. 中山大学附属第一医院 胃肠外科,广东 广州 510080
- 2. 中山大学附属第一医院 药学部,广东 广州 510080
- 折叠
摘要
KIT外显子 9 突变是胃肠间质瘤第二常见的基因突变类型,较其他类型呈现恶性度更高的生物学行为.大多数KIT外显子 9 突变胃肠间质瘤经标准序贯治疗后并不能获得满意的无进展生存期.本文报道了 1 例 44 岁晚期KIT外显子 9 突变女性患者,在标准二线治疗进展后予阿伐替尼联合舒尼替尼治疗,1 个月后肿瘤退缩达 15.7%,获得手术机会.患者术后继续靶向联合治疗,截至2023 年 7 月,共有 6 个月未见肿瘤复发.
Abstract
KIT exon 9 mutation is the second most common genotype of gastrointestinal stromal tumors.It exhibits a more malignant biological behavior than other mutation types.Most KIT exon 9 mutant gastrointestinal stromal tumors cannot obtain satisfactory progression free survival after standard sequential therapy.This article reports a 44-year-old female patient with advanced KIT exon 9 mutation gastrointestinal stromal tumor who was treated with avapritinib combined with sunitinib after progression on standard second-line therapy.The tumor shrunk by 15.7%after one month,following with surgery.The patient continued combination targeted therapy after surgery,and no tumor recurrence has been seen for 6 months until July 2023.
关键词
胃肠间质瘤/KIT外显子9/阿伐替尼/舒尼替尼/靶向联合治疗Key words
Gastrointestinal stromal tumors/KIT exon 9/Avapritinib/Sunitinib/Combination targeted therapy引用本文复制引用
基金项目
白求恩·胃肠间质瘤精准治疗专项研究基金(2021)(WCJZL202104)
出版年
2024
NETL
NSTL
万方数据